Cardiac allograft vasculopathy prevention: Difference between revisions

Jump to navigation Jump to search
Aarti Narayan (talk | contribs)
Aarti Narayan (talk | contribs)
Line 13: Line 13:
** [[Cyclosporine]]
** [[Cyclosporine]]
** [[Tacrolimus]]
** [[Tacrolimus]]
* [[Rapamycin]] derivatives, such as
* [[Immunosuppressive drugs#Drugs Acting on Immunophilins|Rapamycin derivatives]], such as
** [[Sirolimus]]
** [[Sirolimus]]
** [[Everolimus]]
** [[Everolimus]]

Revision as of 19:22, 1 October 2014

Template:Cardiac Allograft Vasculopathy Editor-In-Chief: C. Michael Gibson, M.S., M.D. [1]; Associate Editor(s)-in-Chief: Aarti Narayan, M.B.B.S [2] Raviteja Guddeti, M.B.B.S. [3]

Overview

Prevention

As the pathogenesis of CAV consists of both immunological and non-immunological insults, preventative strategies should consist of control of risk factors for CAV and optimal immunosuppressive therapy.

Optimization of Immunosuppressive Therapy

Options for immunosuppressive therapy for prevention of CAV includes:

References

Template:WH Template:WS